Pacira BioSciences, Inc.
PCRX · Nasdaq · United States
Share price · PCRX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when PCRX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 8 Oct 2026+44.4%
- 5 Aug 2026-10.0%
- 26 May 2026+4.3%
Nothing announced by PCRX that day or the session before.
- 6 May 2026-4.4%
Nothing announced by PCRX that day or the session before.
- 27 Apr 2026+4.2%
Nothing announced by PCRX that day or the session before.
- 16 Jan 2026-7.2%
Nothing announced by PCRX that day or the session before.
- 15 Jan 2026-7.1%
Nothing announced by PCRX that day or the session before.
- 13 Jan 2026-5.8%
Nothing announced by PCRX that day or the session before.
- 9 Jan 2026-9.6%
Nothing announced by PCRX that day or the session before.
- 2 Jan 2026-5.5%
Nothing announced by PCRX that day or the session before.
Share of unusual movement by asset
For each asset, the share of PCRX's own-move activity since 3 Nov 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 65% |
| Sessions with no dated event | — | 35% |
No dated announcements about its assets since 3 Nov 2025.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | Amide Local AnestheticSmall molecule | Acute Pain |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $177M | $27M | $247M+ $49M short-term inv. | —$50M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $192M | $30M | $206M+ $45M short-term inv. | —$57M operating cash flow | report ↗ |
| 2026-Q1 | $177M | $28M | $144M+ $58M short-term inv. | —$26M operating cash flow | report ↗ |
| 2025-Q3 | $180M | $26M | $148M+ $99M short-term inv. | —$61M operating cash flow | report ↗ |
| 2025-Q2 | $181M | $28M | $300M+ $145M short-term inv. | $4.8M$12M operating cash flow | report ↗ |
| 2025-Q1 | $169M | $25M | $284M+ $210M short-term inv. | —$35M operating cash flow | report ↗ |
| 2024-Q3 | $169M | $19M | $246M+ $208M short-term inv. | $143M$54M operating cash flow | report ↗ |
| 2024-Q2 | $178M | $20M | $247M+ $157M short-term inv. | —$53M operating cash flow | report ↗ |
| 2024-Q1 | $167M | $18M | $184M+ $142M short-term inv. | —$49M operating cash flow | report ↗ |
| 2023-Q3 | $164M | $21M | $99M+ $136M short-term inv. | —$44M operating cash flow | report ↗ |
| 2023-Q2 | $169M | $19M | $87M+ $134M short-term inv. | —$44M operating cash flow | report ↗ |
| 2023-Q1 | $160M | $17M | $36M+ $138M short-term inv. | $20M$19M operating cash flow | report ↗ |
| 2022-Q3 | $167M | $19M | $109M+ $219M short-term inv. | $0.7M$43M operating cash flow | report ↗ |
| 2022-Q2 | $169M | $26M | $122M+ $194M short-term inv. | —$30M operating cash flow | report ↗ |
| 2022-Q1 | $158M | $22M | $227M+ $225M short-term inv. | —$31M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $726M | $117M | $159M+ $80M short-term inv. | —$152M operating cash flow | report ↗ |
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $701M | $82M | $277M+ $208M short-term inv. | $25M$189M operating cash flow | report ↗ |
| 2023-FY | $675M | $76M | $153M+ $125M short-term inv. | —$155M operating cash flow | report ↗ |
| 2022-FY | $667M | $85M | $104M+ $185M short-term inv. | —$145M operating cash flow | report ↗ |
| 2021-FY | $539M | $56M | $586M+ $71M short-term inv. | —$126M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 15 sales ($2.4M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-17 | SLONIN JONATHAN · Chief Medical Officer | Disposition to issuer | 216,729.67 | $36.50 | $7.9M | Form 4 |
| 2026-11-17 | Brege Laura · director | Code U | 23,715 | $36.50 | $866K | Form 4 |
| 2026-11-17 | RIKER LAUREN · Senior Vice President, Finance | Code U | 6,881.242 | $36.50 | $251K | Form 4 |
| 2026-11-17 | WIGGANS THOMAS G · director | Disposition to issuer (derivative) | 32,675 | — | — | Form 4 |
| 2026-11-17 | BIGAL MARCELO · director | Code U | 11,393 | $36.50 | $416K | Form 4 |
| 2026-11-17 | Froimson Mark · director | Code U | 20,136 | $36.50 | $735K | Form 4 |
| 2026-11-17 | Cross Shawn · Chief Financial Officer | Code U | 9,210 | $36.50 | $336K | Form 4 |
| 2026-11-17 | CHRISTIE CHRISTOPHER · director | Code U | 16,654 | $36.50 | $608K | Form 4 |